Amarin Pharma Seeks Supreme Court Intervention in Patent Dispute with Hikma Pharmaceuticals

In a recent legal development, Amarin Pharma has petitioned the U.S. Supreme Court to reject Hikma Pharmaceuticals’ attempt to dismiss an induced infringement lawsuit. Amarin argues that the case remains in its early stages. The company contends that Hikma is seeking a way to avoid litigation entirely, which they believe is premature given the situation’s current standing. For further insights into the proceedings, you can read more about the case on Law360.